NNNN · Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology, a Cayman Islands exempted company, has issued proxy materials for two critical shareholder meetings scheduled for May 15, 2026, in Frankfurt am Main, Germany. The first is a Class A Ordinary Shares meeting to approve any variation or abrogation of Class A rights arising from six inter-conditional EGM proposals. The EGM follows immediately and seeks approval for transformative capital structure changes. Key among these is Proposal 1, a special resolution to reduce the par value of authorized shares from US$0.0001 to US$0.000000001, shrinking total authorized capital from US$50,000 to US$0.50 while maintaining 500 million shares initially. Proposal 2 then authorizes a massive expansion to US$3,000 across 3 trillion shares, introducing 1 trillion each of new Class C Ordinary Shares and Preference Shares alongside expanded Class A and B Ordinary Shares, all governed by the proposed Restated M&A. This dilution potential is significant for existing shareholders. Proposal 3 enhances Class B voting power tenfold to 500 votes per share, and Proposal 4 adds convertibility of Class B into Class A shares. Proposal 5 grants the board broad discretion for one or more Class A reverse stock splits (2:1 to 10,000:1 aggregate) over three years to comply with Nasdaq rules, with no fractional shares and rounding up authorized. Proposal 6 adopts the Restated M&A, incorporating these changes plus raising shareholder meeting requisition thresholds to a majority of voting rights, adding exclusive Cayman Islands forum provisions, director resignation notice requirements, and minor updates. Interested Shareholders holding both classes will abstain from the Class A vote. The board unanimously recommends voting 'FOR' all proposals, signaling intent to realign capital for future flexibility amid Nasdaq compliance pressures. Record date is April 22, 2026, with materials distributed around April 27.